Pfizer (PFE) stock emerged from its one-month trading range as the stock surged more than 4% higher on Tuesday.
The mega pharmaceutical company moved higher on strong volume after the company updated investors on its current quarter’s earnings projections.
For the quarter reported February 4, 2025, Pfizer management reaffirmed its revenue guidance of $17.37 billion. The company also expects its earnings per share results to fall within analyst expectations of $0.48.
Pfizer’s announcement to jump start the stock comes at a time that most pharma companies have seen extended selling.
For the month, the SPDR Pharmaceutical ETF (XPH) is trading 1% lower. in comparison, Pfizer whare are nearly 6% higher including today’s gains.
Investors have been in the bearish side of the sector as regulators and lawmakers have increased scrutiny over pricing on several of the larger operators in the industry. Most companies like Pfizer have had strong performance with the popular GLP-1 line of treatments. Those treatments are matriculating to a wider scope of pharma companies, evening the profit filed.
Despite today’s strength, Pfizer shares are trading deep in a long-term bear market trend. The stock crossed into bearish territory in early 2023 as demand for pandemic treatments declined rapidly. The company stock is currently trading 50% lower than its 2022 highs.
Investors looking for a rebound in Pfizer stock may consider waiting through early 2025. The company’s February earnings results are likely to be pivotal in the stock’s ability to maintain its recent bounce. Pfizer’s bearish trending 50- and 200-day moving averages remain just above $27.
The stock’s recent lows of $25 should be considered a “must hold” price for Pfizer. A break below that price would quickly target a move to $20.
